INTRODUCTION
Therapeutic antibodies form one of the fastest growing segments of the pharmaceutical market, expected to more than triple in value between 2002
and 2008. The success of current marketed products has led to an escalation in antibody development, with more than 370 programs currently in the
pipeline. Evolutions in innovation and business model dynamics will drive the sector's dominant position.
SCOPE OF THE REPORT
- Benchmarking of the current and future antibody market, by technology and therapeutic focus, in terms of number of projects and dollar value
- Full profiles of 15 leading antibody players, encompassing company strategy, alliance networking, portfolio and pipeline analysis
- Analysis of market trends and future opportunities for both biotech and pharmaceutical players, with case study analysis
- A virtual dialogue based on extensive interviews with leading players, including Symphogen, CAT, MorphoSys, Affibody, Domantis, Medarex and
Genway
REPORT HIGHLIGHTS
The therapeutic antibody market will triple in size over the next five years with 21 new products, led by humanized and fully human platforms,
launching between 2003-08. However, in terms of market share, chimeric antibodies led by Remicade and Rituxan will continue to dominate.
Achieving a
strong competitive position will require a high degree of innovation. This must be achieved by lowering development times, innovative molecular
engineering, robust intellectual property protection and the development of cost-effective manufacturing.
KEY REASONS TO BUY THIS REPORT
- Benchmark your position within the antibody market and identify the optimum strategy for future technological and supply chain management
- Identify the opportunities provided by current and future innovation evolution to effectively plan your product and technology licensing
strategies
- Optimize your market penetration through comprehensive knowledge of current sales, growth drivers and corporate dynamics of the antibodies
market
View Cart
